Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders

• DOI: 10.1038/tp.2015.185
• Publication Date: 2015-12-08T14:59:29Z
• Authors: M A Frye; M Nassan; G D Jenkins; S Kung; M Veldic; B A Palmer; S E Feeder; S J Tye; D S Choi; J M Biernacka
• Keywords: Biomarker Discovery; Hemopexin; Multiplex

Abstract The objective of this study was to determine whether proteomic profiling in serum samples can be utilized identifying and differentiating mood disorders. A consecutive sample patients with a confirmed diagnosis unipolar (UP n =52) or bipolar depression (BP-I =46, BP-II =49) controls ( =141) were recruited. 7.5-ml blood drawn for multiplex 320 proteins utilizing the Myriad RBM Discovery Multi-Analyte Profiling platform. After correcting multiple testing adjusting covariates, growth differentiation factor 15 (GDF-15), hemopexin (HPX), hepsin (HPN), matrix metalloproteinase-7 (MMP-7), retinol-binding protein 4 (RBP-4) transthyretin (TTR) all showed statistically significant differences among groups. In series three post hoc analyses testing, MMP-7 significantly different disorder (BP-I+BP-II+UP) vs controls, MMP-7, GDF-15, HPN cases (BP-I+BP-II) HPX, HPN, RBP-4 TTR BP-I controls. Good diagnostic accuracy (ROC-AUC⩾0.8) obtained most notably when comparing While based on small not adjusted medication state, discovery conservative method correction suggests feasibility using panels assist distinguishing disorders, particular I disorder. Replication studies confirmation, consideration state trait serial assays delineate expression previous mania, utility assess as an advanced decision making tool companion are encouraged.